ReviewFrontiers in pharmacology2021
Pharmacology, Toxicology, and Metabolism of Sennoside A, A Medicinal Plant-Derived Natural Compound.
Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 62 citations in OpenAlex.
- Translational Pharmaceutical Perspectives on Quinones as Antioxidant and Antidiabetic Agents in Diabetes and Its Complications.Pharmaceutics · 2026Review
- Sennoside A Ameliorates Myocardial Fibrosis After Myocardial Infarction by Binding to KDM4B and Regulates IRX2 Expression.Cardiovascular drugs and therapy · 2026Article
- Intermittent Fasting Amplifies Gut-Endocrine Axis Responses to Senna alexandrina Supplementation in Obese Rats.Molecular nutrition & food research · 2026Article
- Review
- Role of gut microbiota in melanosis coli: from anthraquinone biotransformation to mucosal homeostasis dysbiosis.Frontiers in pharmacology · 2026Review
- Article
- Improving Constipation in Critical Care Patients: A Single-Centre Prospective Cohort Closed-Loop Clinical Audit.Cureus · 2026Article
- Evaluation of the Antibacterial Activity ofCurrent pharmaceutical design · 2026Article
- Integrated Network Pharmacology and Molecular Modeling Approach for Potential PTGS2 Inhibitors against Rheumatoid Arthritis.Current pharmaceutical design · 2026Article
- Association of Initial Laxative Strategy With Clinical Outcomes in Critically Ill Patients With Acute Myocardial Infarction: A Retrospective Cohort Study.Cardiovascular therapeutics · 2026Article
- Sennoside A alleviates sepsis-triggered acute kidney injury via activating SIRT1 signaling pathway.Journal of molecular histology · 2025Article
- Article
- Phytochemical Profile, Vasodilatory and Biphasic Effects on Intestinal Motility, and Toxicological Evaluation of the Methanol and Dichloromethane Extracts from the Aerial Parts ofPharmaceuticals (Basel, Switzerland) · 2025Article
- Sennoside A represses the malignant phenotype and tumor immune microenvironment of non-small cell lung cancer cells by inhibiting the TRAF6/NF-κB pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- UPLC-MS/MS Analysis of Hydroxyanthracene Derivatives in Botanical Food Products and Supplements: Surveillance of the Italian Market.Foods (Basel, Switzerland) · 2025Article
- Insights into the Sources, Structure, and Action Mechanisms of Quinones on Diabetes: A Review.Molecules (Basel, Switzerland) · 2025Review
- Physiological and Metabolic Effects ofLife (Basel, Switzerland) · 2025Article
- Photoaffinity probe-enabled discovery of sennoside A reductase inJournal of pharmaceutical analysis · 2025Article
- Rhubarb: Traditional Uses, Phytochemistry, Multiomics-Based Novel Pharmacological and Toxicological Mechanisms.Drug design, development and therapy · 2025Review
- Chinese herbal medicines: the modifier of hepatocellular carcinoma targeting Wnt/β-catenin signaling pathway.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sennoside A (SA) is a natural dianthrone glycoside mainly from medicinal plants of Senna and Rhubarb, and used as a folk traditional irritant laxative and slimming health food. Accumulating evidences suggest that SA possesses numerous pharmacological properties, such as laxative, anti-obesity, hypoglycemic, hepatoprotective, anti-fibrotic, anti-inflammatory, anti-tumor, anti-bacterial, anti-fungal, anti-viral, and anti-neurodegenerative activities. These pharmacological effects lay the foundation for its potential application in treating a variety of diseases. However, numerous published studies suggest that a long-term use of SA in large doses may have some adverse effects, including the occurrence of melanosis coli and carcinogenesis of colon cancer, thereby limiting its clinical use. It remains to be established whether SA or its metabolites are responsible for the pharmacological and toxicity effects. In this review, the latest advances in the pharmacology, toxicology, and metabolism of SA were summarizedbased on its biological characteristics and mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.